| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, Global Mfg/ Tech Ops | EVP, Technical Operations
1 company
Robert Baffi is President, Global Mfg/ Tech Ops at BMRN. Robert Baffi's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.5M at current prices.
The BMRN filings lean toward selling, a net 30,537 shares.
Robert Baffi has 27 Form 4 filings on record from June 2016 to February 2026, across 3 companies: Director at Neurogene (NGNE), 2024–2026; Director at Mosaic ImmunoEngineering (CPMV), 2022; President, Global Mfg/ Tech Ops at Biomarin Pharmaceutical (BMRN), 2016–2020.
The 40 reported transactions were 14 tax withholdings, 12 stock awards, 7 option or other derivative awards and 5 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $2.9M.
The largest open-market sale was 18,415 shares of BMRN at an average $92.43 on September 28, 2017, about $1.7M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, Technical Operations | Sell | 5,173 | $105.00 | $543,165.00 | -6.7% | |
| Jun 22, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, Technical Operations | Sale+OE | 6,949 | $99.00 | $687,954.28 | -7.7% | |
| Sep 28, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, Technical Operations | Sell | 18,415 | $92.43 | $1,702,030.50 | -39.0% |